Literature DB >> 9234794

Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

D Nardelli-Haefliger1, R B Roden, J Benyacoub, R Sahli, J P Kraehenbuhl, J T Schiller, P Lachat, A Potts, P De Grandi.   

Abstract

Attenuated strains of Salmonella are attractive live vaccine candidates for eliciting mucosal as well as systemic immune responses. The ability to induce immune responses in the reproductive tract may be critical for the effectiveness of a prophylactic vaccine against genital human papillomaviruses (HPV), which are important etiologic agents in the development of cervical cancer. To examine the potential of a live Salmonella-based vaccine to prevent genital HPV infection, the L1 major capsid protein from HPV type 16 (HPV16) was constitutively expressed in the PhoPc strain of Salmonella typhimurium. As demonstrated by electron microscopy, the L1 protein expressed in these bacteria assembled into virus-like particles (VLPs) that resemble authentic papillomavirus virions. This is the first demonstration that papillomavirus VLPs can self-assemble in prokaryotes. BALB/c mice were immunized with the HPV16 L1 recombinant PhoPc strain by the oral and nasal routes. Despite a low stability of the L1-expressing plasmid in vivo, a double nasal immunization was effective in inducing L1-specific serum antibodies that recognized mainly native, but not disassembled, VLPs. These antibodies effectively neutralized HPV16 pseudotyped virions in an in vitro infectivity assay. Conformationally dependent anti-VLP immunoglobulin A (IgA) and IgG were also detected in oral and vaginal secretions, indicating that potentially protective antibody responses were elicited at mucosal sites. Recombinant attenuated Salmonella expressing HPV capsids may represent a promising vaccine candidate against genital HPV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234794      PMCID: PMC175471          DOI: 10.1128/iai.65.8.3328-3336.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways.

Authors:  P G Holt; S Haining; D J Nelson; J D Sedgwick
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

2.  Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination.

Authors:  F Schödel; D R Milich; H Will
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

3.  Secretory immunity in the female reproductive tract.

Authors:  W H Kutteh; J Mestecky
Journal:  Am J Reprod Immunol       Date:  1994-01       Impact factor: 3.886

4.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Authors:  R C Rose; R C Reichman; W Bonnez
Journal:  J Gen Virol       Date:  1994-08       Impact factor: 3.891

5.  Glycosylation of human papillomavirus type 16 L1 protein.

Authors:  J Zhou; X Y Sun; I H Frazer
Journal:  Virology       Date:  1993-05       Impact factor: 3.616

6.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe.

Authors:  T Sasagawa; P Pushko; G Steers; S E Gschmeissner; M A Hajibagheri; J Finch; L Crawford; M Tommasino
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

Review 7.  Genital human papillomavirus infection.

Authors:  D R Lowy; R Kirnbauer; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

8.  Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies.

Authors:  M E Hagensee; J J Carter; G C Wipf; D A Galloway
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

9.  Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination.

Authors:  J P Bouvet; L Bélec; R Pirès; J Pillot
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  46 in total

1.  Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments.

Authors:  F Velge-Roussel; P Marcelo; A C Lepage; D Buzoni-Gatel; D T Bout
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells.

Authors:  Karina Araujo Aires; Aurora Marques Cianciarullo; Sylvia Mendes Carneiro; Luisa Lina Villa; Enrique Boccardo; Gaspar Pérez-Martinez; Isabel Perez-Arellano; Maria Leonor Sarno Oliveira; Paulo Lee Ho
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

Review 5.  Virus-like particles production in green plants.

Authors:  Luca Santi; Zhong Huang; Hugh Mason
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

6.  Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.

Authors:  Sonia Domingos-Pereira; Valérie Cesson; Mathieu F Chevalier; Laurent Derré; Patrice Jichlinski; Denise Nardelli-Haefliger
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

7.  Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Authors:  Patrick R Harrington; Boyd Yount; Robert E Johnston; Nancy Davis; Christine Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.

Authors:  N Hanumantha Rao; P Baji Babu; L Rajendra; R Sriraman; Yuk-Ying S Pang; John T Schiller; V A Srinivasan
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 3.641

Review 9.  Human papillomavirus infection with particular reference to genital disease.

Authors:  C Sonnex
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

10.  HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.

Authors:  Xiaofei Yan; Depu Wang; Fengli Liang; Ling Fu; Cheng Guo
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.